{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:02:44Z","timestamp":1781103764214,"version":"3.54.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01043","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T06:02:36Z","timestamp":1593496956000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection"],"prefix":"10.3389","volume":"10","author":[{"given":"Pil Soo","family":"Sung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaejun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Lim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Chul","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Ik","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Kew","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.21873\/anticanres.13542","article-title":"Reduction of intrahepatic tumour by hepatic arterial infusion chemotherapy prolongs survival in hepatocellular carcinoma","volume":"39","author":"Sung","year":"2019","journal-title":"Anticancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s00259-017-3871-5","article-title":"(18)F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment","volume":"45","author":"Sung","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3350\/cmh.2019.0021n","article-title":"Switching to systemic therapy after locoregional treatment failure: Definition and best timing","volume":"26","author":"Ogasawara","year":"2020","journal-title":"Clin Mol Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s40425-019-0824-5","article-title":"Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions","volume":"7","author":"Hilmi","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1200\/JCO.2018.36.4_suppl.209","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.5582\/bst.2019.01161","article-title":"Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma","volume":"13","author":"Yao","year":"2019","journal-title":"Biosci Trends."},{"key":"B10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/apt.15573","article-title":"Review article: new therapeutic interventions for advanced hepatocellular carcinoma","volume":"51","author":"Bangaru","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1758835919862692","DOI":"10.1177\/1758835919862692","article-title":"Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives","volume":"11","author":"Xu","year":"2019","journal-title":"Ther Adv Med Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s40425-019-0749-z","article-title":"Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response","volume":"7","author":"Keenan","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31187.","article-title":"Treatment of hepatocellular carcinoma in the Precision Medicine era: from treatment stage migration to therapeutic hierarchy","author":"Vitale","year":"2020","journal-title":"Hepatology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jhep.2019.05.014","article-title":"Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced asian cohort analysis","volume":"71","author":"Yau","year":"2019","journal-title":"J Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1136\/gutjnl-2019-318912","article-title":"Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas","volume":"68","author":"Zhang","year":"2019","journal-title":"Gut."},{"key":"B16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.21037\/hbsn.2019.08.10","article-title":"Heterogenous responses to nivolumab in a single metastatic nodule in hepatocellular carcinoma: role of salvage surgery","volume":"8","author":"Yang","year":"2019","journal-title":"Hepatobiliary Surg Nutr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3350\/cmh.2018.0090","article-title":"Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Mol Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","year":"2018","journal-title":"J Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Society for immunotherapy of cancer toxicity management working, managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00432-018-2780-8","article-title":"Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers","volume":"145","author":"Finkelmeier","year":"2019","journal-title":"J Cancer Res Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/cancers12010182","article-title":"Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature."},{"key":"B26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fmed.2019.00119","article-title":"Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events","volume":"6","author":"Nakamura","year":"2019","journal-title":"Front Med (Lausanne)."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-18-3340","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab","volume":"24","author":"Joseph","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.21873\/anticanres.13180","article-title":"Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer","volume":"39","author":"Katsurada","year":"2019","journal-title":"Anticancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2019.11.014","article-title":"Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan","volume":"140","author":"Morita","year":"2020","journal-title":"Lung Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/apt.13904","article-title":"The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development","volume":"45","author":"Pinato","year":"2017","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01043\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T06:02:39Z","timestamp":1593496959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01043\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":33,"alternative-id":["10.3389\/fonc.2020.01043"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01043","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"article-number":"1043"}}